Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma

Hai-ying Wang, Jun-feng Chu, Peng Zhang, Jia-qiang Wang, Zheng Yan, Shu-na Yao, Zhi-hua Yao, Yan-yan Liu Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, People’s Republic of ChinaCorrespondence: Zhi-hua Yao; Hai-...

Full description

Bibliographic Details
Main Authors:	Wang H, Chu J, Zhang P, Wang J, Yan Z, Yao S, Yao Z, Liu Y
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-02-01
Series:	OncoTargets and Therapy
Subjects:	advanced/metastatic soft tissue sarcoma anlotinib chemotherapy toxicity
Online Access:	https://www.dovepress.com/safety-and-efficacy-of-chemotherapy-combined-with-anlotinib-plus-anlot-peer-reviewed-article-OTT

Similar Items

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
by: Liu Z, et al.
Published: (2021-02-01)

A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer
by: Wang H, et al.
Published: (2020-05-01)

Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma
by: Shenglong Li, et al.
Published: (2021-05-01)

Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma
by: Zhi‐Ming Wang, et al.
Published: (2020-05-01)

Trabectedin for Metastatic Soft Tissue Sarcoma: A Retrospective Single Center Analysis
by: Anthony D. Ho, et al.
Published: (2010-10-01)

Systemic chemotherapy of advanced soft tissue sarcomas
by: Mehmet Besiroglu, et al.
Published: (2017-07-01)

A Case Report of Advanced Lung Adenocarcinoma Harboring KRAS Mutation  Treated with Anlotinib
by: Yudong SU, et al.
Published: (2018-05-01)

Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation
by: Jian-zhou Cao, et al.
Published: (2021-05-01)

The efficacy and safety of anlotinib treatment for advanced lung cancer
by: Shao L, et al.
Published: (2019-08-01)

Multi-Omics Analysis of Anlotinib in Pancreatic Cancer and Development of an Anlotinib-Related Prognostic Signature
by: Xi Zhang, et al.
Published: (2021-03-01)

Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer
by: Nanlin Hu, et al.
Published: (2021-08-01)

Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial
by: Jing Huang, et al.
Published: (2021-03-01)

Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study
by: Zhong Q, et al.
Published: (2021-05-01)

Hypertensive Retinopathy Secondary to Anlotinib Treatment
by: Xiaohua Zhang, et al.
Published: (2020-06-01)

Anlotinib Combined With Chemotherapy for Recurrence of Pulmonary Sarcomatoid Cancer Previously Surgically Treated: A Case Report and Literature Review
by: Jing Li, et al.
Published: (2021-05-01)

Aortic dissection in a patient treated with anlotinib for metastatic lung squamous cell carcinoma
by: Bailing Jiang, et al.
Published: (2020-02-01)

Exosomal miR-136-5p Derived from Anlotinib-Resistant NSCLC Cells Confers Anlotinib Resistance in Non-Small Cell Lung Cancer Through Targeting PPP2R2A
by: Gu G, et al.
Published: (2021-09-01)

Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial
by: Jianhui Ma, et al.
Published: (2020-05-01)

A Case Report of Targeted Therapy with Anlotinib in a Patient with Advanced Breast Metaplastic Carcinoma
by: Zou J, et al.
Published: (2021-08-01)

Clinical Efficacy of Anlotinib Combined with Paclitaxel and Cisplatin as First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma
by: YANG Xiaoli, et al.
Published: (2021-07-01)

Anlotinib as Exploratory Therapy for Platinum-Resistant Ovarian Cancer: A Retrospective Study on Efficacy and Safety
by: Ni J, et al.
Published: (2020-10-01)

Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new
by: Anna Maria Frezza, et al.
Published: (2017-06-01)

Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
by: Guoshuang Shen, et al.
Published: (2018-09-01)

Anlotinib Plus S-1 for Patients with EGFR Mutation-Negative Advanced Squamous Cell Lung Cancer with PS Scores of 2–3 After Progression of Second-Line or Later-Line Treatment
by: Xie XH, et al.
Published: (2020-12-01)

Longitudinal Pharmacometabonomics for Predicting Malignant Tumor Patient Responses to Anlotinib Therapy: Phenotype, Efficacy, and Toxicity
by: Ting Hu, et al.
Published: (2020-11-01)

In vitro studies of H520 cell cycle and apoptosis by anlotinib combined with radiotherapy
by: Lu Guo, et al.
Published: (2021-03-01)

Salvage treatment with anlotinib for advanced non‐small cell lung cancer
by: Di Wu, et al.
Published: (2019-07-01)

Anlotinib Suppresses Colorectal Cancer Proliferation and Angiogenesis via Inhibition of AKT/ERK Signaling Cascade
by: Yang Q, et al.
Published: (2020-06-01)

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
by: Yongkun Sun, et al.
Published: (2016-10-01)

Bronchial Fistula: Rare Complication of Treatment with Anlotinib
by: Pengbo DENG, et al.
Published: (2020-10-01)

Anlotinib Inhibits PFKFB3-Driven Glycolysis in Myofibroblasts to Reverse Pulmonary Fibrosis
by: Weimou Chen, et al.
Published: (2021-09-01)

A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
by: Cui Q, et al.
Published: (2021-01-01)

Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report
by: Biyong Ren, et al.
Published: (2021-06-01)

iCREATE: imaging features of primary and metastatic alveolar soft part sarcoma from the EORTC CREATE study
by: Naami Charlotte Mcaddy, et al.
Published: (2020-10-01)

The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma
by: Yan Song, et al.
Published: (2021-05-01)

The Impact of Neo-adjuvant and Adjuvant Chemotherapy in Treatment Outcome of Patients with High Risk Soft Tissue Sarcomas of the Extremities
by: Rasha Hamdy Hamed, et al.
Published: (2012-04-01)

Anlotinib Exerts Anti-Cancer Effects on KRAS-Mutated Lung Cancer Cell Through Suppressing the MEK/ERK Pathway
by: Hu H, et al.
Published: (2020-05-01)

The Activity and Safety of Anlotinib for Patients with Extremity Desmoid Fibromatosis: A Retrospective Study in a Single Institution
by: Zheng C, et al.
Published: (2020-09-01)

A Serum Metabolomic Study Reveals Changes in Metabolites During the Treatment of Lung Cancer-Bearing Mice with Anlotinib
by: Pan X, et al.
Published: (2021-08-01)

Clinical Efficacy of Anlotinib as Second-line Treatment on Patients with Extensive Small Cell Lung Cancer
by: LIN Jianguang, et al.
Published: (2020-12-01)